Why MAP4K2 is the Next Big Target in the Pancreatic Cancer (With Experimental Protocols)

NanoEntek
Apr 1
2 min read

A recent study has revealed new insights into the role of MAP4K2 in pancreatic cancer. In this blog, we provide a concise summary of the key findings and their implications.

Overview

MAP4K2 triggers regulatory T cells (Tregs) and suppresses anti-tumor immune responses.
MAP4K2 is a kinase that promotes the generation of immunosuppressive Tregs, inhibiting anti-tumor immune responses. Thus, blocking MAP4K2 was shown to enhance anti-tumor efficacy, particularly by synergizing with PD-1 checkpoint inhibition.

Purpose

The purpose of this study was to demonstrate MAP4K2-mediated immune regulation
in vivo, especially to study the function of MAP4K2 in tumors.

Samples

Mice: T-MAP4K2 cKO (T-cell specific MAP4K2 conditional KO), Foxp3-Cre (Treg-specific MAP4K2-deficient), and wild-type subcutaneously injected with KPC pancreatic cancer cells

- Usage to compare the tumor volume (Fig.8, 9)

- Used to demonstrate whether Treg decreases in the absence of MAP4K2 (Fig.1, 8, 9)

- Used to test the increase in immune efficacy when anti-PD-1 antibodies are added in MAP4K2-deficient mice (Fig.8, 9, 11)

Human: Three healthy individuals (control), 27 patients with pancreatic ductal adenocarcinoma

- Used to test if the same mechanism works in humans

- Healthy individuals were needed to obtain PBMC, naive T cells, and FOXP3

- Patients were needed to obtain T cells in the pancreatic tissue and Tregs

Jurkat T cells:

- Used to confirm if MAP4K2 regulates Foxp3 splicing in T cells (Fig.3, 4, 5)

HEK293 cells:

- Used to confirm the binding of overexpressed DDX39B and MAP4K2 (Fig.3)

Expected Results

✔ MAP4K2 Activation

FOXP3 expression ↑
Treg population ↑

✔ MAP4K2 Inhibition / KO

FOXP3 expression ↓
Treg population ↓
Immune efficacy ↑

Key Insight

MAP4K2 regulates Treg differentiation via RNA splicing control of FOXP3.

Conclusion

MAP4K2 serves as a critical regulator of Treg differentiation through FOXP3 RNA splicing. Targeting this pathway provides a powerful strategy to enhance anti-tumor immunity.

Electroporation Protocol

In this study, ExTransfection^™ was used with the following protocol:

	Voltage	Width	Pulse
Jurkat T cells	1430 V	30 ms	1 pulse
Primary T cells	2200 V	30 ms	1 pulse

ExTransfection^™ provides optimized protocols for Jurkat cells and T cells, ensuring high transfection efficiency and viability.

Cell line	Cell type	Morphology	Voltage (V)	Width (ms)	Pulse	Cell density (cells/mL)	Tip (μL)
Jurkat	Blood, Human	Lymphoblast, Suspension	1380	30	1	5 × 10⁶	10
Jurkat	Blood, Human	Lymphoblast, Suspension	1410	30	1	5 × 10⁶	100
Jurkat	Blood, Human	Lymphoblast, Suspension	1600	20	1	2.5 x 10⁷	10
Jurkat	Blood, Human	Lymphoblast, Suspension	1700	20	1	2.5 x 10⁷	10
Jurkat	Blood, Human	Lymphoblast, Suspension	1400	30	1	2.5 x 10⁷	10
Jurkat	Blood, Human	Lymphoblast, Suspension	1100	20	4	2.5 x 10⁷	10
T cell	Primary	Lymphocyte, Suspension	2100	20	1	2.0 x 10⁷	10
T cell	Primary	Lymphocyte, Suspension	2000	15	2	2.0 x 10⁷	10